ISRCTN ISRCTN94372129
DOI https://doi.org/10.1186/ISRCTN94372129
Secondary identifying numbers Rostock01
Submission date
25/11/2011
Registration date
30/03/2012
Last edited
17/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Stem cell mobilization is a process where drugs are used to cause the movement of stem cells so that they can be collected and used for a stem cell transplant. The drug ratiograstim has been approved for the mobilization of peripheral stem cells (from the bloodstream). The aim of this study is to assess the effectiveness and safety of peripheral stem cell mobilization by either ratiograstim or the reference drug G-CSF.

Who can participate?
Patients undergoing a stem cell transplant for hematological malignancies (cancers that affect the blood and lymph system) and their related healthy donors

What does the study involve?
Participating donors are treated with either ratiograstim or G-CSF and the effectiveness and safety of the two drugs is compared.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Universität Heidelberg (Germany)

When is the study starting and how long is it expected to run for?
January 2010 to November 2011

Who is funding the study?
Ratiopharm GmbH (Germany)

Who is the main contact?
Prof. Michael Schmitt

Contact information

Prof Michael Schmitt
Scientific

Universität Heidelberg
Hämatologie
Grabengasse 1
Heidelberg
69120
Germany

Study information

Study designNon-randomised trial
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please contact mathias.freund@onkologie-rostock.de to request a patient information sheet
Scientific titleApplication of the granulocyte colony-stimulating factor (G-CSF) biosimilar ratiograstim for the mobilisation of peripheral stem cells in healthy donors
Study objectivesEffectivity of the biosimilar ratiograstim is similar to original G-CSF.
Ethics approval(s)Federal Authority (Bundesamt für Arzneimittel, BfArM), 21/07/2010, ref: SNR: 250906/10
Health condition(s) or problem(s) studiedAllogeneic stem cell transplantation
InterventionTwo cohorts, one cohort of 11 patients and donors receiving the biosimilar Ratiograstim® versus another cohort of 11 patients and donors receiving reference G-CSF. Results in this study arm were compared with results of a matched historical control
Intervention typeProcedure/Surgery
Primary outcome measureEfficacy in peripheral stem cell mobilisation
Secondary outcome measuresSafety in peripheral stem cell mobilisation
Overall study start date01/01/2010
Completion date30/11/2011

Eligibility

Participant type(s)Mixed
Age groupAdult
SexBoth
Target number of participants22
Key inclusion criteria1. Donors had no known allergy to G-CSF
2. Siblings (match-related donors)
Key exclusion criteriaYounger than 18 years
Date of first enrolment01/01/2010
Date of final enrolment30/11/2011

Locations

Countries of recruitment

  • Germany

Study participating centre

Universität Heidelberg
Heidelberg
69120
Germany

Sponsor information

University of Heidelberg (Universität Heidelberg) (Germany)
University/education

c/o Prof. Dr. med. michael schmitt
Hämatologie
Grabengasse 1
Heidelberg
69117
Germany

ROR logo "ROR" https://ror.org/038t36y30

Funders

Funder type

Industry

Ratiopharm GmbH (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/07/2013 Yes No

Editorial Notes

17/10/2017: Plain English summary and publication reference added.